[1]
|
VILLANUEVA M T. Conscious uncoupling in NASH[J]. Nat Rev Drug Discov,2017,16(4):239 |
[2]
|
NEUSCHWANDER-TETRI B A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites[J]. Hepatology,2010,52(2):774-788 |
[3]
|
MARRA F, SVEGLIATI-BARONI G. Lipotoxicity and the gut-liver axis in NASH pathogenesis[J]. J Hepatol,2018,68(2):280-295 |
[4]
|
PEVERILL W, POWELL L, SKOIEN R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation[J]. Int J Mol Sci,2014,15(5):8591-8638 |
[5]
|
LAZIC M, INZAUGARAT M E, POVERO D, et al. Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis[J]. Plos One,2014,9(9):e107658 |
[6]
|
ABDELMALEK M F, SUZUKI A, GUY C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease[J]. Hepatology,2010,51(6):1961-1971 |
[7]
|
IOANNOU G N, VAN ROOYEN D M, SAVARD C, et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH[J]. J Lipid Res,2015,56(2):277-285 |
[8]
|
MIELE L C, MARRONE G, LAURITANO C, et al. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target[J]. Curr Pharm Des,2013,19(29):5314-5324 |
[9]
|
SCHRODER K, TSCHOPP J. The inflammasomes[J]. Cell,2010,140(6):821-832 |
[10]
|
MINKIEWICZ J, DE RIVERO VACCARI J P, KEANE R W. Human astrocytes express a novel NLRP2 inflammasome[J]. Glia,2013,61(7):1113-1121 |
[11]
|
Wlodarska M, Thaiss CA, Nowarski R, et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion[J]. Cell,2014,156(5):1045-1059 |
[12]
|
OHASHI K, WANG Z J, YANG Y M, et al. NOD-like receptor C4 inflammasome regulates the growth of colon cancer liver metastasis in NAFLD[J]. Hepatology,2019:30693 |
[13]
|
DING J J, WANG K, LIU W, et al. Pore-forming activity and structural autoinhibition of the gasdermin family[J]. Nature,2016,535(7610):111-116 |
[14]
|
WREE A, MCGEOUGH M D, PEÑA C A, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD[J]. J Mol Med,2014,92(10):1069-1082 |
[15]
|
MATSUZAKA T, ATSUMI A, MATSUMORI R, et al. Elovl6 promotes nonalcoholic steatohepatitis[J]. Hepatology,2012,56(6):2199-2208 |
[16]
|
WEN H T, GRIS D, LEI Y, et al. Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling[J]. Nat Immunol,2011,12(5):408-415 |
[17]
|
WREE A, EGUCHI A, MCGEOUGH M D, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice[J]. Hepatology,2014,59(3):898-910 |
[18]
|
MRIDHA A R, WREE A, ROBERTSON A A B, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice[J]. J Hepatol,2017,66(5):1037-1046 |
[19]
|
YANG S J, LIM Y. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation[J]. Metabolism,2014,63(5):693-701 |
[20]
|
XU B, JIANG M, CHU Y, et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice[J]. J Hepatol,2018,68(4):773-782 |
[21]
|
MIURA K, KODAMA Y, INOKUCHI S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice[J]. Gastroenterology,2010,139(1):323-334.e7 |
[22]
|
STIENSTRA R, SAUDALE F, DUVAL C, et al. Kupffer cells promote hepatic steatosis via interleukin-1β-dependent suppression of peroxisome proliferator-activated receptor α activity[J]. Hepatology,2010,51(2):511-522 |
[23]
|
VANDANMAGSAR B, YOUM Y, RAVUSSIN A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance[J]. Nat Med,2011,17(2):179-188 |
[24]
|
PETRASEK J, BALA S S, CSAK T, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice[J]. J Clin Invest,2012,122(10):3476-3489 |
[25]
|
WITEK R P, STONE W C, KARACA F G, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis[J]. Hepatology,2009,50(5):1421-1430 |
[26]
|
KIM S H, KIM G, HAN D H, et al. Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition[J]. Autophagy,2017,13(10):1767-1781 |
[27]
|
HENAO-MEJIA J, ELINAV E, JIN C C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J]. Nature,2012,482(7384):179-185 |
[28]
|
DE MINICIS S, RYCHLICKI C, AGOSTINELLI L, et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice[J]. Hepatology,2014,59(5):1738-1749 |
[29]
|
CSAK T, PILLAI A, GANZ M, et al. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis[J]. Liver Int,2014,34(9):1402-1413 |
[30]
|
MURPHY A J, KRAAKMAN M J, KAMMOUN H L, et al. IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome[J]. Cell Metab,2016,23(1):155-164 |
[31]
|
ANITHA M, REICHARDT F, TABATABAVAKILI S, et al. Intestinal dysbiosis contributes to the delayed gastrointestinal transit in high-fat diet fed mice[J]. Cell Mol Gastroenterol Hepatol,2016,2(3):328-339 |
[32]
|
CHEN G Y, LIU M C, WANG F Y, et al. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis[J]. J Immunol,2011,186(12):7187-7194 |
[33]
|
ZHANG Q, RAOOF M, CHEN Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury[J]. Nature,2010,464(7285):104-107 |
[34]
|
SUN Q, LOUGHRAN P, SHAPIRO R, et al. Redox-dependent regulation of hepatocyte absent in melanoma 2 inflammasome activation in sterile liver injury in mice[J]. Hepatology,2017,65(1):253-268 |
[35]
|
WATANABE A, SOHAIL M A, GOMES D A, et al. Inflammasome-mediated regulation of hepatic stellate cells[J]. Am J Physiol Gastrointest Liver Physiol,2009,296(6):G1248-G1257 |
[36]
|
WREE A, MCGEOUGH M D, INZAUGARAT M E, et al. NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice[J]. Hepatology,2018,67(2):736-749 |